A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

A Randomized, Double-blind, Placebo-controlled, Dose Ranging, Parallel, Multi-center, Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat

This study is a randomized, double-blind, placebo-controlled, dose-ranging, parallel, multi-center, phase II study to evaluate the efficacy and safety of MT921 in subjects with moderate to severe submental fat.

Inclusion Criteria:

• Subjects over 19 and under 65 years old
• Subjects achieving CA-SMFRS and PA-SMFRS score of 2 or 3
• Subjects who voluntarily signed the Informed Consent

Exclusion Criteria:

• Subjects who had liposuction or other procedures on the treatment area that might affect the assessment.
• Subjects with BMI over 35.0kg/m^2
• Subjects with dysphagia
• Subjects who are allergic or hypersensitive to the investigational product
• Subjects who are pregnant or lactating, or does not agree to use an accepatble form of contraception during the clinical trial.
• Subjects who are otherwise deemed uneligible by the investigator.